“52-Week Safety and Efficacy of Amlitelimab in Participants With Moderate-to-Severe Atopic Dermatitis: Preliminary Analysis from the Open-Label Long-Term ATLANTIS Trial”. SKIN The Journal of Cutaneous Medicine 10, no. 3 (May 11, 2026): s780. Accessed May 14, 2026. https://skin.dermsquared.com/skin/article/view/4242.